Article

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment

Inserm, U676, Hôpital Robert Debré, Paris, F-75019 France and Université Paris 7, Faculté de Médecine Denis Diderot, IFR02, Paris, France.
BMC Neurology (Impact Factor: 2.49). 02/2008; 8:20. DOI: 10.1186/1471-2377-8-20
Source: PubMed

ABSTRACT Friedreich ataxia is a neurological disease originating from an iron-sulfur cluster enzyme deficiency due to impaired iron handling in the mitochondrion, aconitase being particularly affected. As a mean to counteract disease progression, it has been suggested to chelate free mitochondrial iron. Recent years have witnessed a renewed interest in this strategy because of availability of deferiprone, a chelator preferentially targeting mitochondrial iron.
Control and Friedreich's ataxia patient cultured skin fibroblasts, frataxin-depleted neuroblastoma-derived cells (SK-N-AS) were studied for their response to iron chelation, with a particular attention paid to iron-sensitive aconitase activity.
We found that a direct consequence of chelating mitochondrial free iron in various cell systems is a concentration and time dependent loss of aconitase activity. Impairing aconitase activity was shown to precede decreased cell proliferation.
We conclude that, if chelating excessive mitochondrial iron may be beneficial at some stage of the disease, great attention should be paid to not fully deplete mitochondrial iron store in order to avoid undesirable consequences.

0 Followers
 · 
113 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurodegenerative disorders such as Friedreich ataxia (FRDA) present significant challenges in developing effective therapeutic intervention. Current treatments aim to manage symptoms and thus improve quality of life, but none can cure, nor are proven to slow, the neurodegeneration inherent to this disease. The primary clinical features of FRDA include progressive ataxia and shortened life span, with complications of cardiomyopathy being the major cause of death. FRDA is most commonly caused by an expanded GAA trinucleotide repeat in the first intron of FXN which leads to reduced levels of frataxin, a mitochondrial protein important for iron metabolism. The GAA expansion in FRDA does not alter the coding sequence of FXN. It results in reduced production of structurally normal frataxin and hence any increase in protein level is expected to be therapeutically beneficial. Recently, there has been increased interest in developing novel therapeutic applications like cell and/or gene therapies and these cutting-edge applications could provide effective treatment options for FRDA. Importantly, since individuals with FRDA produce frataxin at low levels, increased expression should not elicit an immune response. Here we review the advances to date and highlight the potential for cell and gene therapy to treat this debilitating disease.
    Human gene therapy 04/2014; 25(8). DOI:10.1089/hum.2013.180 · 3.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Friedreich's ataxia (FRDA) is a neurological disease related to a deficiency of the protein frataxin involved in iron–sulfur (Fe–S) cluster biogenesis. This leads to an increased cellular iron uptake accumulating in mitochondria, and a subsequently disturbed iron homeostasis. The detailed mechanism of iron regulation of frataxin expression is yet unknown. Deferiprone, an iron chelator that may cross the blood–brain barrier, was shown to shuttle iron between subcellular compartments. It could also transfer iron from iron-overloaded cells to extracellular apotransferrin and pre-erythroid cells for heme synthesis. Here, clinical studies on Deferiprone are reviewed in the context of alternative agents such as desferoxamine, with specific regard to its mechanistic and clinical implications.
    Journal of Neurochemistry 08/2013; 126(s1). DOI:10.1111/jnc.12300 · 4.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: We conducted a 6-month randomized, double-blind, placebo-controlled study to assess safety, tolerability, and efficacy of deferiprone in Friedreich’s ataxia.Methods: Seventy-two patients were treated with deferiprone 20, 40, or 60 mg/kg/day or placebo, divided into two daily doses. Safety was the primary objective, secondary objectives included standardized neurological assessments (FARS, ICARS, 9HPT, T25FW, LCLA), general functional status (ADL), and cardiac assessments.Results: Deferiprone was well tolerated at 20 mg/kg/day, whereas more adverse events occurred in the 40 mg/kg/day than in the placebo group. The 60mg/kg/day dose was discontinued due to worsening of ataxia in two patients. One patient on deferiprone 20 mg/kg/day experienced reversible neutropenia, but none developed agranulocytosis. Deferiprone-treated patients receiving 20 or 40 mg/kg/day showed a decline in the LV mass index, compared to an increase in the placebo-treated patients. Patients receiving 20 mg/kg/day of deferiprone had no significant change in FARS, similar to the placebo-treated patients, while those receiving 40 mg/kg/day had worsening in FARS and ICARS scores. The lack of deterioration in the placebo arm impaired the ability to detect any potential protective effect of deferiprone. However, subgroup analyses in patients with less severe disease suggested a benefit of deferiprone 20 mg/kg/day on ICARS, FARS, kinetic function and 9HPT.Interpretation: This study demonstrated an acceptable safety profile of deferiprone at 20 mg/kg/day for the treatment of patients with FRDA. Subgroup analyses raise the possibility that, in patients with less severe disease, deferiprone 20 mg/kg/day may reduce disease progression, while higher doses appear to worsen ataxia. ANN NEUROL 2014. © 2014 American Neurological Association
    Annals of Neurology 10/2014; 76(4). DOI:10.1002/ana.24248 · 11.91 Impact Factor

Preview (2 Sources)

Download
0 Downloads
Available from